MetaADEDB 2.0 @ LMMD
Cannabidiol
(QHMBSVQNZZTUGM-ZWKOTPCHSA-N)
Structure
SMILES
CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C
Type(s)
Approved; Investigational
ATC code(s)
N03AX24
Molecular Formula:
C21H30O2
Molecular Weight:
314.462
Log P:
5.8465
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
2
TPSA:
40.46
CAS Number(s):
3556-78-3; 13956-29-1
Synonym(s)
1.
Cannabidiol
External Link(s)
MeSHD002185
PubChem Compound644019
BindingDB50121429
50318484
ChEBI69478
CHEMBLCHEMBL190461
DrugBankDB09061
IUPHAR/BPS Guide to PHARMACOLOGY4150
KEGGcpd:C07578
dr:D10915
Therapeutic Target DatabaseD0O1UZ
ZINC4097406
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1SomnolenceFAERS: 24US FAERS
2Product dose omissionFAERS: 17US FAERS
3FatigueFAERS: 13US FAERS
4ConstipationFAERS: 12US FAERS
5VomitingFAERS: 921827451CTD
US FAERS
6Drug ineffectiveFAERS: 8US FAERS
7LethargyFAERS: 8US FAERS
8NauseaFAERS: 621827451CTD
US FAERS
9AstheniaFAERS: 5US FAERS
10PneumoniaFAERS: 5US FAERS
11DroolingFAERS: 4US FAERS
12Gait inabilityFAERS: 4US FAERS
13HeadacheFAERS: 4US FAERS
14HypersomniaFAERS: 4US FAERS
15Status EpilepticusFAERS: 4US FAERS
16Urinary tract infectionFAERS: 4US FAERS
17Weight decreasedFAERS: 4US FAERS
18InfluenzaFAERS: 3US FAERS
19NasopharyngitisFAERS: 3US FAERS
20AcneFAERS: 2US FAERS
21AgitationFAERS: 2US FAERS
22Ammonia increasedFAERS: 2US FAERS
23AnxietyFAERS: 2US FAERS
24ChromaturiaFAERS: 2US FAERS
25DehydrationFAERS: 2US FAERS
26EpilepsyFAERS: 2US FAERS
27Feeling abnormalFAERS: 2US FAERS
28Lip swellingFAERS: 2US FAERS
29MalaiseFAERS: 2US FAERS
30PancreatitisFAERS: 2US FAERS
31Poverty of speechFAERS: 2US FAERS
32Product supply issueFAERS: 2US FAERS
33PruritusFAERS: 2US FAERS
34RestlessnessFAERS: 2US FAERS
35SepsisFAERS: 2US FAERS
36ShockFAERS: 2US FAERS
37ThirstFAERS: 2US FAERS
38TremorFAERS: 2US FAERS
39Abdominal PainFAERS: 1US FAERS
40Abdominal discomfortFAERS: 1US FAERS
41Acute kidney injuryFAERS: 1US FAERS
42AlopeciaFAERS: 1US FAERS
43AngerFAERS: 1US FAERS
44AngioedemaFAERS: 1US FAERS
45Ankle FractureFAERS: 1US FAERS
46AphasiaFAERS: 1US FAERS
47Blood alkaline phosphatase decreasedFAERS: 1US FAERS
48ChillsFAERS: 1US FAERS
49ChokingFAERS: 1US FAERS
50CholelithiasisFAERS: 1US FAERS
51Clostridium difficile infectionFAERS: 1US FAERS
52Dark circles under eyesFAERS: 1US FAERS
53Decreased eye contactFAERS: 1US FAERS
54Device battery issueFAERS: 1US FAERS
55DizzinessFAERS: 1US FAERS
56Dry skinFAERS: 1US FAERS
57DyspepsiaFAERS: 1US FAERS
58Emotional disorderFAERS: 1US FAERS
59Enzyme level increasedFAERS: 1US FAERS
60ErythemaFAERS: 1US FAERS
61Feeling ColdFAERS: 1US FAERS
62FlushingFAERS: 1US FAERS
63Focal dyscognitive seizuresFAERS: 1US FAERS
64General physical health deteriorationFAERS: 1US FAERS
65HypophagiaFAERS: 1US FAERS
66Impaired gastric emptyingFAERS: 1US FAERS
67Inappropriate affectFAERS: 1US FAERS
68Inappropriate schedule of product administrationFAERS: 1US FAERS
69InfectionFAERS: 1US FAERS
70Intentional self-injuryFAERS: 1US FAERS
71Intestinal ObstructionFAERS: 1US FAERS
72Lower respiratory tract infection viralFAERS: 1US FAERS
73Lower respiratory tract infectionFAERS: 1US FAERS
74Medical device site irritationFAERS: 1US FAERS
75Mental status changesFAERS: 1US FAERS
76Neck PainFAERS: 1US FAERS
77Night sweatsFAERS: 1US FAERS
78NocturiaFAERS: 1US FAERS
79Obsessive-Compulsive DisorderFAERS: 1US FAERS
80Product availability issueFAERS: 1US FAERS
81Product container issueFAERS: 1US FAERS
82Product dispensing errorFAERS: 1US FAERS
83Product quality issueFAERS: 1US FAERS
84Product taste abnormalFAERS: 1US FAERS
85Product use issueFAERS: 1US FAERS
86Quality of life decreasedFAERS: 1US FAERS
87Respiratory distressFAERS: 1US FAERS
88RetchingFAERS: 1US FAERS
89Retinal migraineFAERS: 1US FAERS
90Rhinovirus infectionFAERS: 1US FAERS
91SinusitisFAERS: 1US FAERS
92Skin lacerationFAERS: 1US FAERS
93Therapeutic product effect decreasedFAERS: 1US FAERS
94TonsillitisFAERS: 1US FAERS
95Visual ImpairmentFAERS: 1US FAERS
96Abnormalities, Drug-Induced29106691CTD
97Bipolar Disorder19939866CTD
98Cognition Disorders21350020CTD
99Dyslipidemias31499052CTD
100Dystonia3793381CTD
101Hyperglycemia31499052CTD
102Hypotension3793381CTD
103Liver diseases31499052CTD
104Memory Disorders16406104CTD
105Micronuclei, Chromosome-Defective30341733CTD
106Neoplasm Metastasis22198381CTD
107Poisoning23552853CTD
108Prenatal Exposure Delayed Effects30594692CTD
109Psychoses, Substance-Induced16612464CTD
110Schizophrenia16612464CTD
111Seizures

View details

841172
10605059
26283212
29106691
 		CTD
112Xerostomia3793381CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.